Rifaximin Demonstrates Superior Adherence and Faster Symptom Relief Compared to Low FODMAP Diet in Irritable Bowel Syndrome

Highlights

• Rifaximin and the Low FODMAP Diet (LFD) show comparable composite symptom improvement at four weeks, but Rifaximin offers significantly faster relief for bloating and abdominal pain by week two.
• Patient adherence to Rifaximin therapy (95.9%) is significantly higher than adherence to the restrictive low FODMAP diet (77.8%), highlighting practical advantages in clinical management.
• Rifaximin treatment in IBS patients with SIBO not only improves symptoms but also increases lactase activity, potentially reversing secondary lactose intolerance.

Introduction: Navigating Second-Line Therapies for IBS